Studies focused on the significance of CD133 expression in RC have demonstrated that CD133-positive cells exhibit stronger resistance to chemoradiotherapy protocols and a risk of cancer recurrence compared to CD133-negative cells [7,19,26]. This evidence concerns the gene PROM1 and cancer.